Clinical Trials Logo

Myotonic Muscular Dystrophy clinical trials

View clinical trials related to Myotonic Muscular Dystrophy.

Filter by:
  • None
  • Page 1

NCT ID: NCT05027269 Completed - Clinical trials for Myotonic Dystrophy 1

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

MARINA
Start date: October 28, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients (MARINA). Part A is a single dose design with 1 cohort (dose level). In Part A, the patient duration is 6 months as the treatment period is 1 day followed by a 6 month follow-up period. Part B is a multiple-ascending dose design with 2 cohorts (dose levels). In Part B, the patient duration is 6 months as the treatment period is 3 months followed by a 3 month follow-up period.

NCT ID: NCT00082108 Recruiting - Muscular Dystrophy Clinical Trials

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

Start date: September 2000
Phase:
Study type: Observational

Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are inherited disorders characterized by progressive muscle weakness and loss of muscle tissue. The purpose of this registry is to connect people with DM or FSHD with researchers studying these diseases. The registry will offer individuals with DM and FSHD an opportunity to participate in research that focuses of their diseases. The registry will also help scientists to accomplish research on DM and FSHD and to distribute their findings to patients and care providers.

NCT ID: NCT00004769 Completed - Clinical trials for Myotonic Muscular Dystrophy

Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy

Start date: December 1993
Phase: N/A
Study type: Observational

OBJECTIVES: I. Examine the interrelationships between muscle wasting (phenotype), the degree of myotonic dystrophy (DM) gene expression (genotype) in patients with DM. II. Characterize the insulin resistance in these patients. III. Assess the glucose uptake in the leg and forearm tissues of these patients. IV. Determine the stability of the DM gene lesion in muscles over a 5-10 year period.